Mohs’ Micrographic Surgery of the Periorbital Area

  • Michael R. MigdenEmail author
  • Sirunya Silapunt


Mohs micrographic surgery (MMS) provides one of the highest cure rates and may be more tissue sparing than other methods of surgical resection. It is a preferred treatment for most periorbital malignancies. The most common periorbital cancers treated with MMS include basal cell carcinoma, squamous cell carcinoma, and sebaceous carcinoma. MMS is not appropriate in certain circumstances for which other therapy such as wide local excision should be considered. A multidisciplinary combination of Mohs micrographic surgery, oculoplastic reconstructive surgery, and other medical and surgical specialties provides optimal patient care when treating periorbital cutaneous cancers. MMS for melanoma is controversial and not accepted at most centers due to the complexities encountered using frozen section histological evaluation. Modified MMS may be appropriate for some types of periorbital malignancy.


Sentinel Lymph Node Biopsy Basal Cell Carcinoma Merkel Cell Carcinoma Wide Local Excision Nevoid Basal Cell Carcinoma Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Mohs FE. Micrographic surgery for the microscopically controlled excision of eyelid cancers. Arch Ophthalmol. 1986;104(6):901–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Menn H, Robins P, Kopf AW, Bart RS. The recurrent basal cell epithelioma. A study of 100 cases of recurrent, re-treated basal cell epitheliomas. Arch Dermatol. 1971;103(6):628–31.PubMedCrossRefGoogle Scholar
  3. 3.
    Kumar B, Roden D, Vinciullo C, Elliott T. A review of 24 cases of Mohs surgery and ophthalmic plastic reconstruction. Aust N Z J Ophthalmol. 1997;25(4):289–93.PubMedCrossRefGoogle Scholar
  4. 4.
    Brodland DG, Amonette R, Hanke CW, Robins P. The history and evolution of Mohs micrographic surgery. Dermatol Surg. 2000;26(4):303–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Baylis HI, Cies WA. Complications of Mohs’ chemosurgical excision of eyelid and canthal tumors. Am J Ophthalmol. 1975;80(1):116–22.PubMedGoogle Scholar
  6. 6.
    Mohs F. Chemosurgery: microscopically controlled surgery for skin cancer. Springfield: Thomas, C; 1978.Google Scholar
  7. 7.
    Drake LA, Dinehart SM, Goltz RW, et al. Guidelines of care for Mohs micrographic surgery. American academy of dermatology. J Am Acad Dermatol. 1995;33(2 Pt 1):271–8.PubMedGoogle Scholar
  8. 8.
    Minton TJ. Contemporary Mohs surgery applications. Curr Opin Otolaryngol Head Neck Surg. 2008;16(4):376–80.PubMedCrossRefGoogle Scholar
  9. 9.
    Malhotra R, Huilgol SC, Huynh NT, Selva D. The Australian Mohs database, part I: periocular basal cell carcinoma experience over 7 years. Ophthalmology. 2004;111(4):624–30.PubMedCrossRefGoogle Scholar
  10. 10.
    Monheit GD, Callahan MA, Callahan A. Mohs micrographic surgery for periorbital skin cancer. Dermatol Clin. 1989;7(4):677–97.PubMedGoogle Scholar
  11. 11.
    Robins P, Rodriguez-Sains R, Rabinovitz H, Rigel D. Mohs surgery for periocular basal cell carcinomas. J Dermatol Surg Oncol. 1985;11(12):1203–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Malhotra R, Huilgol SC, Huynh NT, Selva D. The Australian Mohs database, part II: periocular basal cell carcinoma outcome at 5-year follow-up. Ophthalmology. 2004;111(4):631–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Nemet AY, Deckel Y, Martin PA, et al. Management of periocular basal and squamous cell carcinoma: a series of 485 cases. Am J Ophthalmol. 2006;142(2):293–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Miller PK, Roenigk RK, Brodland DG, Randle HW. Cutaneous micrographic surgery: Mohs procedure. Mayo Clin Proc. 1992;67(10):971–80.PubMedCrossRefGoogle Scholar
  15. 15.
    Arlette JP, Carruthers A, Threlfall WJ, Warshawski LM. Basal cell carcinoma of the periocular region. J Cutan Med Surg. 1998;2(4):205–8.PubMedGoogle Scholar
  16. 16.
    Callahan A, Monheit GD, Callahan MA. Cancer excision from eyelids and ocular adnexa: the Mohs fresh tissue technique and reconstruction. CA Cancer J Clin. 1982;32(6):322–29.PubMedCrossRefGoogle Scholar
  17. 17.
    Donaldson MJ, Sullivan TJ, Whitehead KJ, Williamson RM. Periocular keratoacanthoma: clinical features, pathology, and management. Ophthalmology. 2003;110(7):1403–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Cottel WI. Perineural invasion by squamous-cell carcinoma. J Dermatol Surg Oncol. 1982;8(7):589–600.PubMedCrossRefGoogle Scholar
  19. 19.
    Faustina M, Diba R, Ahmadi MA, Esmaeli B. Patterns of regional and distant metastasis in patients with eyelid and periocular squamous cell carcinoma. Ophthalmology. 2004;111(10):1930–2.PubMedCrossRefGoogle Scholar
  20. 20.
    Sullivan TJ, Boulton JE, Whitehead KJ. Intraepidermal carcinoma of the eyelid. Clin Experiment Ophthalmol. 2002;30(1):23–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Malhotra R, James CL, Selva D, Huynh N, Huilgol SC. The Australian Mohs database: periocular squamous intraepidermal carcinoma. Ophthalmology. 2004;111(10):1925–9.PubMedGoogle Scholar
  22. 22.
    Smith KJ, Skelton HG, Holland TT. Recent advances and controversies concerning adnexal neoplasms. Dermatol Clin. 1992;10(1):117–60.PubMedGoogle Scholar
  23. 23.
    Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. Cancer. 2009;115(1):158–65.PubMedCrossRefGoogle Scholar
  24. 24.
    Cook Jr BE, Bartley GB. Treatment options and future prospects for the management of eyelid malignancies: an evidence-based update. Ophthalmology. 2001;108(11):2088–98; quiz 2099–2100, 2121.PubMedCrossRefGoogle Scholar
  25. 25.
    Ratz JL, Luu-Duong S, Kulwin DR. Sebaceous carcinoma of the eyelid treated with Mohs’ surgery. J Am Acad Dermatol. 1986;14(4):668–73.PubMedCrossRefGoogle Scholar
  26. 26.
    O’Neal ML, Brunson A, Spadafora J. Ocular sebaceous carcinoma: case report and review of the literature. Compr Ther. 2001;27(2):144–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Husain A, Blumenschein G, Esmaeli B. Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol. 2008;47(3):276–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Rao NA, Hidayat AA, McLean IW, Zimmerman LE. Sebaceous carcinomas of the ocular adnexa: a clinicopathologic study of 104 cases, with five-year follow-up data. Hum Pathol. 1982;13(2):113–22.PubMedCrossRefGoogle Scholar
  29. 29.
    Chao AN, Shields CL, Krema H, Shields JA. Outcome of patients with periocular sebaceous gland carcinoma with and without conjunctival intraepithelial invasion. Ophthalmology. 2001;108(10):1877–83.PubMedCrossRefGoogle Scholar
  30. 30.
    Snow SN, Larson PO, Lucarelli MJ, Lemke BN, Madjar DD. Sebaceous carcinoma of the eyelids treated by Mohs micrographic surgery: report of nine cases with review of the literature. Dermatol Surg. 2002;28(7):623–31.PubMedCrossRefGoogle Scholar
  31. 31.
    Arora A, Barlow RJ, Williamson JM, Olver JM. Eyelid sebaceous gland carcinoma (SGC) treated with ‘slow’ Mohs’ micrographic surgery. Eye (Lond). 2004;18(8):854–5.CrossRefGoogle Scholar
  32. 32.
    Yount AB, Bylund D, Pratt SG, Greenway HT. Mohs micrographic excision of sebaceous carcinoma of the eyelids. J Dermatol Surg Oncol. 1994;20(8):523–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Dzubow LM. Sebaceous carcinoma of the eyelid: treatment with Mohs surgery. J Dermatol Surg Oncol. 1985;11(1):40–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Putterman AM. Conjunctival map biopsy to determine pagetoid spread. Am J Ophthalmol. 1986;102(1):87–90.PubMedGoogle Scholar
  35. 35.
    Spencer JM, Nossa R, Tse DT, Sequeira M. Sebaceous carcinoma of the eyelid treated with Mohs micrographic surgery. J Am Acad Dermatol. 2001;44(6):1004–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Dixon RS, Mikhail GR, Slater HC. Sebaceous carcinoma of the eyelid. J Am Acad Dermatol. 1980;3(3):241–3.PubMedCrossRefGoogle Scholar
  37. 37.
    Rigel DS. Cancer of the skin. Philadelphia: Elsevier Saunders; 2005. p. 277–88.Google Scholar
  38. 38.
    Rudkin AK, Muecke JS. Mitomycin-C as adjuvant therapy in the treatment of sebaceous gland carcinoma in high-risk locations. Clin Exp Ophthalmol. 2009;37(4):352–6.CrossRefGoogle Scholar
  39. 39.
    Tumuluri K, Kourt G, Martin P. Mitomycin C in sebaceous gland carcinoma with pagetoid spread. Br J Ophthalmol. 2004;88(5):718–9.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Shields CL, Naseripour M, Shields JA, Eagle Jr RC. Topical mitomycin-C for pagetoid invasion of the conjunctiva by eyelid sebaceous gland carcinoma. Ophthalmology. 2002;109(11):2129–33.PubMedCrossRefGoogle Scholar
  41. 41.
    Savar A, Oellers P, Myers J, et al. Positive sentinel node in sebaceous carcinoma of the eyelid. Ophthal Plast Reconstr Surg. 2011;27(1):e4–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Kivela T, Tarkkanen A. The Merkel cell and associated neoplasms in the eyelids and periocular region. Surv Ophthalmol. 1990;35(3):171–87.PubMedCrossRefGoogle Scholar
  43. 43.
    Rubsamen PE, Tanenbaum M, Grove AS, Gould E. Merkel cell carcinoma of the eyelid and periocular tissues. Am J Ophthalmol. 1992;113(6):674–80.PubMedGoogle Scholar
  44. 44.
    O’Connor WJ, Roenigk RK, Brodland DG. Merkel cell carcinoma. Comparison of Mohs micrographic surgery and wide excision in eighty-six patients. Dermatol Surg. 1997;23(10):929–33.PubMedCrossRefGoogle Scholar
  45. 45.
    Gupta SG, Wang LC, Penas PF, Gellenthin M, Lee SJ, Nghiem P. Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature. Arch Dermatol. 2006;142(6):685–90.PubMedGoogle Scholar
  46. 46.
    Lewis KG, Weinstock MA, Weaver AL, Otley CC. Adjuvant local irradiation for Merkel cell carcinoma. Arch Dermatol. 2006;142(6):693–700.PubMedGoogle Scholar
  47. 47.
    Lawenda BD, Arnold MG, Tokarz VA, et al. Analysis of radiation therapy for the control of Merkel cell carcinoma of the head and neck based on 36 cases and a literature review. Ear Nose Throat J. 2008;87(11):634–43.PubMedGoogle Scholar
  48. 48.
    Chiller K, Passaro D, Scheuller M, Singer M, McCalmont T, Grekin RC. Microcystic adnexal carcinoma: forty-eight cases, their treatment, and their outcome. Arch Dermatol. 2000;136(11):1355–9.PubMedGoogle Scholar
  49. 49.
    Snow S, Madjar DD, Hardy S, et al. Microcystic adnexal carcinoma: report of 13 cases and review of the literature. Dermatol Surg. 2001;27(4):401–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Zitelli JA, Brown C, Hanusa BH. Mohs micrographic surgery for the treatment of primary cutaneous melanoma. J Am Acad Dermatol. 1997;37(2 Pt 1):236–45.PubMedCrossRefGoogle Scholar
  51. 51.
    Temple CL, Arlette JP. Mohs micrographic surgery in the treatment of lentigo maligna and melanoma. J Surg Oncol. 2006;94(4):287–92.PubMedCrossRefGoogle Scholar
  52. 52.
    Cohen LM, McCall MW, Zax RH. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. A follow-up study. Dermatol Surg. 1998;24(6):673–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Cohen LM, McCall MW, Hodge SJ, Freedman JD, Callen JP, Zax RH. Successful treatment of lentigo maligna and lentigo maligna melanoma with Mohs’ micrographic surgery aided by rush permanent sections. Cancer. 1994;73(12):2964–70.PubMedCrossRefGoogle Scholar
  54. 54.
    Zitelli JA. Mohs surgery for lentigo maligna. Arch Dermatol. 1991;127(11):1729–30.PubMedCrossRefGoogle Scholar
  55. 55.
    McKenna JK, Florell SR, Goldman GD, Bowen GM. Lentigo maligna/lentigo maligna melanoma: current state of diagnosis and treatment. Dermatol Surg. 2006;32(4):493–504.PubMedCrossRefGoogle Scholar
  56. 56.
    Vaziri M, Buffam FV, Martinka M, Oryschak A, Dhaliwal H, White VA. Clinicopathologic features and behavior of cutaneous eyelid melanoma. Ophthalmology. 2002;109(5):901–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Tahery DP, Goldberg R, Moy RL. Malignant melanoma of the eyelid. A report of eight cases and a review of the literature. J Am Acad Dermatol. 1992;27(1):17–21.PubMedCrossRefGoogle Scholar
  58. 58.
    Garner A, Koornneef L, Levene A, Collin JR. Malignant melanoma of the eyelid skin: histopathology and behaviour. Br J Ophthalmol. 1985;69(3):180–6.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Esmaeli B, Wang B, Deavers M, et al. Prognostic factors for survival in malignant melanoma of the eyelid skin. Ophthal Plast Reconstr Surg. 2000;16(4):250–7.PubMedCrossRefGoogle Scholar
  60. 60.
    Agarwal-Antal N, Bowen GM, Gerwels JW. Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines. J Am Acad Dermatol. 2002;47(5):743–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Shumaker PR, Kelley B, Swann MH, Greenway Jr HT. Modified Mohs micrographic surgery for periocular melanoma and melanoma in situ: long-term experience at Scripps Clinic. Dermatol Surg. 2009;35(8):1263–70.PubMedCrossRefGoogle Scholar
  62. 62.
    Malhotra R, Chen C, Huilgol SC, Hill DC, Selva D. Mapped serial excision for periocular lentigo maligna and lentigo maligna melanoma. Ophthalmology. 2003;110(10):2011–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Kimyai-Asadi A, Katz T, Goldberg LH, et al. Margin involvement after the excision of melanoma in situ: the need for complete en face examination of the surgical margins. Dermatol Surg. 2007;33(12):1434–9; discussion 1439–1441.PubMedGoogle Scholar
  64. 64.
    Bub JL, Berg D, Slee A, Odland PB. Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up. Arch Dermatol. 2004;140(5):552–8.PubMedGoogle Scholar
  65. 65.
    Zitelli JA, Moy RL, Abell E. The reliability of frozen sections in the evaluation of surgical margins for melanoma. J Am Acad Dermatol. 1991;24(1):102–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Dhawan SS, Wolf DJ, Rabinovitz HS, Poulos E. Lentigo maligna. The use of rush permanent sections in therapy. Arch Dermatol. 1990;126(7):928–30.PubMedCrossRefGoogle Scholar
  67. 67.
    Zalla MJ, Lim KK, Dicaudo DJ, Gagnot MM. Mohs micrographic excision of melanoma using immunostains. Dermatol Surg. 2000;26(8):771–84.PubMedCrossRefGoogle Scholar
  68. 68.
    Johnson TM, Headington JT, Baker SR, Lowe L. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the “square” procedure. J Am Acad Dermatol. 1997;37(5 Pt 1):758–64.PubMedCrossRefGoogle Scholar
  69. 69.
    Demirci H, Johnson TM, Frueh BR, Musch DC, Fullen DR, Nelson CC. Management of periocular cutaneous melanoma with a staged excision technique and permanent sections the square procedure. Ophthalmology. 2008;115(12):2295–300, e2293.PubMedCrossRefGoogle Scholar
  70. 70.
    Chang KH, Finn DT, Lee D, Bhawan J, Dallal GE, Rogers GS. Novel 16-minute technique for evaluating melanoma resection margins during Mohs surgery. J Am Acad Dermatol. 2011;64(1):107–12.PubMedCrossRefGoogle Scholar
  71. 71.
    Kimyai-Asadi A, Ayala GB, Goldberg LH, Vujevich J, Jih MH. The 20-minute rapid MART-1 immunostain for malignant melanoma frozen sections. Dermatol Surg. 2008;34(4):498–500.PubMedCrossRefGoogle Scholar
  72. 72.
    Committee on Guidelines of Care. Task Force on Malignant Melanoma. Guidelines of care for malignant melanoma. J Am Acad Dermatol. 1993;28(4):638–41.Google Scholar
  73. 73.
    NIH Consensus conference. Diagnosis and treatment of early melanoma. JAMA. 1992;268(10):1314–19.Google Scholar
  74. 74.
    Beard C. Observations on the treatment of basal cell carcinoma of the eyelids. The Wendell L. Huges Lecture. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1975;79(5):664–70.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Departments of Dermatology and Plastic Surgery, Mohs and Dermasurgery UnitThe University of Texas M.D. Anderson Cancer CenterHoustonUSA
  2. 2.Department of DermatologyUniversity of Texas Medical School at HoustonHoustonUSA

Personalised recommendations